

Print Date: Dec 14th 2021

www.tocris.com

**Product Name: FRAX 486** Catalog No.: 5190 Batch No.: 2

**Certificate of Analysis** 

CAS Number: 1232030-35-1

**IUPAC Name:** 6-(2,4-Dichlorophenyl)-8-ethyl-2-[[3-fluoro-4-(1-piperazinyl)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one

### 1. PHYSICAL AND CHEMICAL PROPERTIES

 $C_{25}H_{23}CI_2FN_6O.\frac{1}{2}H_2O$ **Batch Molecular Formula:** 

**Batch Molecular Weight:** 522.4

Yellow solid **Physical Appearance:** 

DMSO to 20 mM Solubility:

Store at -20°C Storage:

**Batch Molecular Structure:** 

# 2. ANALYTICAL DATA

HPLC: Shows 99.2% purity

<sup>1</sup>H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

> Theoretical 57.48 4.63 16.09 Found 57.41 4.44 15.85



# **Product Information**

Print Date: Dec 14th 2021

www.tocris.com

Product Name: FRAX 486 Catalog No.: 5190 Batch No.: 2

CAS Number: 1232030-35-1

IUPAC Name: 6-(2,4-Dichlorophenyl)-8-ethyl-2-[[3-fluoro-4-(1-piperazinyl)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one

# **Description:**

FRAX 486 is a potent p21-activated kinase (PAK) inhibitor (IC<sub>50</sub> values are 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively). Blocks and reverses the DISC1 knockdown-induced reduction in dendritic spine size in cortical neurons. Attenuates dendritic spine elimination and enhances spine generation in DISC1 knockdown mice. Ameliorates autism-like behavioral symptoms in fragile X mental retardation 1 (Fmr1) knockout mice. Brain penetrant and orally bioavailable.

## **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>25</sub>H<sub>23</sub>Cl<sub>2</sub>FN<sub>6</sub>O.½H<sub>2</sub>O

Batch Molecular Weight: 522.4 Physical Appearance: Yellow solid

Minimum Purity: ≥98%

#### **Batch Molecular Structure:**

Storage: Store at -20°C

### Solubility & Usage Info:

DMSO to 20 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

# References:

**Wang** *et al* (2016) P21-activated kinase inhibitors FRAX486 and IPA3: inhibition of prostate stromal cell growth and effects on smooth muscle contraction in the human prostate. PLoS One *11* e0153312. PMID: 27071060.

**Dolan** et al (2013) Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc.Natl.Acad.Sci.U.S.A. **110** 5671. PMID: 23509247.

Hayashi-Takagi et al (2013) PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc.Natl.Acad.Sci.U.S.A. 111 6461. PMID: 24706880.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

www.tocris.com/distributors Tel:+1 612 379 2956